The global extracorporeal membrane oxygenation machine market is on a growth trajectory, with revenue anticipated to reach ...

SynerFuse, in partnership with the Minneapolis-based University of Minnesota, South Bend (Ind.) Orthopaedics and RQM+, has completed the first proof-of-concept study of its electric transforaminal ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Starting today, people with Parkinson’s disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.

Medtronic [MDT] is a major medical technology company ... alongside significant acquisitions such as its purchase of Nanovis’ nanotechnology for use in spinal implants, then the strength of its ...

This patent relates to cochlear implant systems having a cochlear electrode, a stimulator in electrical communication with the cochlear electrode, an inner ear sensor, and a signal processor in ...